Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Remicade Infusion Management Program.

Trial Profile

Remicade Infusion Management Program.

Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2013

At a glance

  • Drugs Infliximab (Primary)
  • Indications Crohn's disease; Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RemiTRAC
  • Sponsors Janssen Inc; Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 14 Jan 2013 Actual initiation date changed from Jul 2005 to Aug 2005 as reported by ClinicalTrials.gov.
    • 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 30 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top